Curation
PascalFrancis
Racine
Curation
Checkpoint
PascalFrancis
Racine
PascalFrancis
Exploration
Accueil
Racine
Racine

Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset

Identifieur interne : 003766 ( PascalFrancis/Curation ); précédent : 003765; suivant : 003767

De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset

Auteurs : R. K. B. Pearce [Royaume-Uni] ; T. Banerji ; P. Jenner ; C. D. Marsden

Source :

RBID : Pascal:98-0177441

Descripteurs français

English descriptors

pA  
A01 01  1    @0 0885-3185
A03   1    @0 Mov. disord.
A05       @2 13
A06       @2 2
A08 01  1  ENG  @1 De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset
A11 01  1    @1 PEARCE (R. K. B.)
A11 02  1    @1 BANERJI (T.)
A11 03  1    @1 JENNER (P.)
A11 04  1    @1 MARSDEN (C. D.)
A14 01      @1 Neurodegenerative Diseases Research Centre, Pharmacology Group, Biomedical Sciences Division, King College @2 London @3 GBR
A14 02      @1 National Hospital for Neurology and Neurosurgery @3 GBR
A20       @1 234-241
A21       @1 1998
A23 01      @0 ENG
A43 01      @1 INIST @2 20953 @5 354000079238580060
A44       @0 0000 @1 © 1998 INIST-CNRS. All rights reserved.
A45       @0 42 ref.
A47 01  1    @0 98-0177441
A60       @1 P
A61       @0 A
A64   1    @0 Movement disorders
A66 01      @0 USA
C02 01  X    @0 002B02U01
C03 01  X  FRE  @0 Parkinson maladie @5 01
C03 01  X  ENG  @0 Parkinson disease @5 01
C03 01  X  SPA  @0 Parkinson enfermedad @5 01
C03 02  X  FRE  @0 Dyskinésie @5 04
C03 02  X  ENG  @0 Dyskinesia @5 04
C03 02  X  SPA  @0 Disquinesia @5 04
C03 03  X  FRE  @0 Lévodopa @5 07
C03 03  X  ENG  @0 Levodopa @5 07
C03 03  X  SPA  @0 Levodopa @5 07
C03 04  X  FRE  @0 Chimiothérapie @5 08
C03 04  X  ENG  @0 Chemotherapy @5 08
C03 04  X  SPA  @0 Quimioterapia @5 08
C03 05  X  FRE  @0 Antiparkinsonien @5 09
C03 05  X  ENG  @0 Antiparkinson agent @5 09
C03 05  X  SPA  @0 Antiparkinsoniano @5 09
C03 06  X  FRE  @0 Bromocriptine @2 NK @2 FR @5 10
C03 06  X  ENG  @0 Bromocriptine @2 NK @2 FR @5 10
C03 06  X  SPA  @0 Bromocriptina @2 NK @2 FR @5 10
C03 07  X  FRE  @0 Agoniste @5 11
C03 07  X  ENG  @0 Agonist @5 11
C03 07  X  SPA  @0 Agonista @5 11
C03 08  X  FRE  @0 Récepteur dopaminergique D2 @5 12
C03 08  X  ENG  @0 D2 Dopamine receptor @5 12 @6 «D2» Dopamine receptor
C03 08  X  SPA  @0 Receptor dopaminérgico D2 @5 12
C03 09  X  FRE  @0 Ropinirole @2 NK @2 FR @5 13
C03 09  X  ENG  @0 Ropinirole @2 NK @2 FR @5 13
C03 09  X  SPA  @0 Ropinirol @2 NK @2 FR @5 13
C03 10  X  FRE  @0 De novo @5 14
C03 10  X  ENG  @0 De novo @5 14
C03 10  X  SPA  @0 De novo @5 14
C03 11  X  FRE  @0 Relation dose réponse @5 16
C03 11  X  ENG  @0 Dose activity relation @5 16
C03 11  X  SPA  @0 Relación dosis respuesta @5 16
C03 12  X  FRE  @0 Traitement @5 17
C03 12  X  ENG  @0 Treatment @5 17
C03 12  X  GER  @0 Aufbereiten @5 17
C03 12  X  SPA  @0 Tratamiento @5 17
C03 13  X  FRE  @0 Toxicité @5 18
C03 13  X  ENG  @0 Toxicity @5 18
C03 13  X  GER  @0 Giftigkeit @5 18
C03 13  X  SPA  @0 Toxicidad @5 18
C03 14  X  FRE  @0 Etude comparative @5 19
C03 14  X  ENG  @0 Comparative study @5 19
C03 14  X  GER  @0 Vergleich @5 19
C03 14  X  SPA  @0 Estudio comparativo @5 19
C03 15  X  FRE  @0 Singe @5 20
C03 15  X  ENG  @0 Monkey @5 20
C03 15  X  SPA  @0 Mono @5 20
C03 16  X  FRE  @0 Animal adulte @5 21
C03 16  X  ENG  @0 Adult animal @5 21
C03 16  X  SPA  @0 Animal adulto @5 21
C07 01  X  FRE  @0 Primates @2 NS
C07 01  X  ENG  @0 Primates @2 NS
C07 01  X  SPA  @0 Primates @2 NS
C07 02  X  FRE  @0 Mammalia @2 NS
C07 02  X  ENG  @0 Mammalia @2 NS
C07 02  X  SPA  @0 Mammalia @2 NS
C07 03  X  FRE  @0 Vertebrata @2 NS
C07 03  X  ENG  @0 Vertebrata @2 NS
C07 03  X  SPA  @0 Vertebrata @2 NS
C07 04  X  FRE  @0 Système nerveux pathologie @5 37
C07 04  X  ENG  @0 Nervous system diseases @5 37
C07 04  X  SPA  @0 Sistema nervioso patología @5 37
C07 05  X  FRE  @0 Système nerveux central pathologie @5 38
C07 05  X  ENG  @0 Central nervous system disease @5 38
C07 05  X  SPA  @0 Sistema nervosio central patología @5 38
C07 06  X  FRE  @0 Encéphale pathologie @5 39
C07 06  X  ENG  @0 Cerebral disorder @5 39
C07 06  X  SPA  @0 Encéfalo patología @5 39
C07 07  X  FRE  @0 Extrapyramidal syndrome @5 40
C07 07  X  ENG  @0 Extrapyramidal syndrome @5 40
C07 07  X  SPA  @0 Extrapiramidal síndrome @5 40
C07 08  X  FRE  @0 Maladie dégénérative @5 41
C07 08  X  ENG  @0 Degenerative disease @5 41
C07 08  X  SPA  @0 Enfermedad degenerativa @5 41
C07 09  X  FRE  @0 Trouble neurologique @5 46
C07 09  X  ENG  @0 Neurological disorder @5 46
C07 09  X  SPA  @0 Trastorno neurológico @5 46
C07 10  X  FRE  @0 Mouvement involontaire @5 47
C07 10  X  ENG  @0 Involuntary movement @5 47
C07 10  X  SPA  @0 Movimiento involuntario @5 47
N21       @1 117

Links toward previous steps (curation, corpus...)

Links to Exploration step

Pascal:98-0177441

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset</title>
<author>
<name sortKey="Pearce, R K B" sort="Pearce, R K B" uniqKey="Pearce R" first="R. K. B." last="Pearce">R. K. B. Pearce</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Neurodegenerative Diseases Research Centre, Pharmacology Group, Biomedical Sciences Division, King College</s1>
<s2>London</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>National Hospital for Neurology and Neurosurgery</s1>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author>
<name sortKey="Banerji, T" sort="Banerji, T" uniqKey="Banerji T" first="T." last="Banerji">T. Banerji</name>
</author>
<author>
<name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P." last="Jenner">P. Jenner</name>
</author>
<author>
<name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">98-0177441</idno>
<date when="1998">1998</date>
<idno type="stanalyst">PASCAL 98-0177441 INIST</idno>
<idno type="RBID">Pascal:98-0177441</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003058</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003766</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset</title>
<author>
<name sortKey="Pearce, R K B" sort="Pearce, R K B" uniqKey="Pearce R" first="R. K. B." last="Pearce">R. K. B. Pearce</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Neurodegenerative Diseases Research Centre, Pharmacology Group, Biomedical Sciences Division, King College</s1>
<s2>London</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>National Hospital for Neurology and Neurosurgery</s1>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author>
<name sortKey="Banerji, T" sort="Banerji, T" uniqKey="Banerji T" first="T." last="Banerji">T. Banerji</name>
</author>
<author>
<name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P." last="Jenner">P. Jenner</name>
</author>
<author>
<name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name>
</author>
</analytic>
<series>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="1998">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult animal</term>
<term>Agonist</term>
<term>Antiparkinson agent</term>
<term>Bromocriptine</term>
<term>Chemotherapy</term>
<term>Comparative study</term>
<term>D2 Dopamine receptor</term>
<term>De novo</term>
<term>Dose activity relation</term>
<term>Dyskinesia</term>
<term>Levodopa</term>
<term>Monkey</term>
<term>Parkinson disease</term>
<term>Ropinirole</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Parkinson maladie</term>
<term>Dyskinésie</term>
<term>Lévodopa</term>
<term>Chimiothérapie</term>
<term>Antiparkinsonien</term>
<term>Bromocriptine</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique D2</term>
<term>Ropinirole</term>
<term>De novo</term>
<term>Relation dose réponse</term>
<term>Traitement</term>
<term>Toxicité</term>
<term>Etude comparative</term>
<term>Singe</term>
<term>Animal adulte</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Singe</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0885-3185</s0>
</fA01>
<fA03 i2="1">
<s0>Mov. disord.</s0>
</fA03>
<fA05>
<s2>13</s2>
</fA05>
<fA06>
<s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>PEARCE (R. K. B.)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>BANERJI (T.)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>JENNER (P.)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>MARSDEN (C. D.)</s1>
</fA11>
<fA14 i1="01">
<s1>Neurodegenerative Diseases Research Centre, Pharmacology Group, Biomedical Sciences Division, King College</s1>
<s2>London</s2>
<s3>GBR</s3>
</fA14>
<fA14 i1="02">
<s1>National Hospital for Neurology and Neurosurgery</s1>
<s3>GBR</s3>
</fA14>
<fA20>
<s1>234-241</s1>
</fA20>
<fA21>
<s1>1998</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>20953</s2>
<s5>354000079238580060</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 1998 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>42 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>98-0177441</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i2="1">
<s0>Movement disorders</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X">
<s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Dyskinésie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Dyskinesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Disquinesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Lévodopa</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Levodopa</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Levodopa</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Chimiothérapie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Chemotherapy</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Quimioterapia</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Antiparkinsonien</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Antiparkinson agent</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Antiparkinsoniano</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Bromocriptine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Bromocriptine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Bromocriptina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Agoniste</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Agonist</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Agonista</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Récepteur dopaminergique D2</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>D2 Dopamine receptor</s0>
<s5>12</s5>
<s6>«D2» Dopamine receptor</s6>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Receptor dopaminérgico D2</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Ropinirole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>Ropinirole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>Ropinirol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE">
<s0>De novo</s0>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG">
<s0>De novo</s0>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA">
<s0>De novo</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE">
<s0>Relation dose réponse</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG">
<s0>Dose activity relation</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA">
<s0>Relación dosis respuesta</s0>
<s5>16</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE">
<s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG">
<s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="GER">
<s0>Aufbereiten</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA">
<s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE">
<s0>Toxicité</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG">
<s0>Toxicity</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="GER">
<s0>Giftigkeit</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA">
<s0>Toxicidad</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE">
<s0>Etude comparative</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG">
<s0>Comparative study</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="GER">
<s0>Vergleich</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA">
<s0>Estudio comparativo</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE">
<s0>Singe</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG">
<s0>Monkey</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA">
<s0>Mono</s0>
<s5>20</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE">
<s0>Animal adulte</s0>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG">
<s0>Adult animal</s0>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA">
<s0>Animal adulto</s0>
<s5>21</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE">
<s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG">
<s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA">
<s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE">
<s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG">
<s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA">
<s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE">
<s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG">
<s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA">
<s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE">
<s0>Trouble neurologique</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG">
<s0>Neurological disorder</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA">
<s0>Trastorno neurológico</s0>
<s5>46</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE">
<s0>Mouvement involontaire</s0>
<s5>47</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG">
<s0>Involuntary movement</s0>
<s5>47</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA">
<s0>Movimiento involuntario</s0>
<s5>47</s5>
</fC07>
<fN21>
<s1>117</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003766 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 003766 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:98-0177441
   |texte=   De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset
}}
Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024